Europe is a central geographic setting in the medical history of hepatitis C virus infection. It combines a substantial population burden with sharp differences between countries, while also providing evidence for changing transmission routes, declining acute incidence, persistent chronic disease, and the growing importance of kidney disease and transplantation in the management of infected patients.

Regional Epidemiology and Diagnosis

In Western Europe, hepatitis C virus prevalence is reported to range from 0.4% to 3%, whereas prevalence is higher in Eastern Europe and the Middle East. Across Europe, hepatitis C virus remains one of the principal causes of chronic liver disease, and the large number of infections is clinically important because many infected people are unaware of their status. The disease burden therefore extends beyond diagnosed cases: chronic infection may persist for decades before cirrhosis, hepatocellular carcinoma, or extrahepatic disease becomes apparent.

European evidence also records a decline in new infections. About 10% of acute hepatitis cases in Europe were attributed to acute hepatitis C virus infection in the cited analysis, while the incidence had fallen to approximately 1 case per 100,000 subjects per year after improved blood-product screening, stricter hygiene, and more effective treatment. That figure was considered an underestimate because 50% to 90% of acute infections may be asymptomatic. Spontaneous resolution occurred in roughly 30% of acute cases, with outcome influenced by the route of transmission, symptomatic presentation, age at infection, immune status, and IL28B genotype.

Diagnosis in Europe depends on separating exposure from active disease. Anti-hepatitis C virus antibodies are detected with third-generation enzyme-linked immunosorbent assays, but antibody positivity alone cannot distinguish resolved infection from chronic infection. Active chronic infection requires detectable hepatitis C virus RNA in serum, measured with sensitive molecular assays whose threshold is approximately 15 IU/ml. This distinction determines whether a patient has evidence of previous exposure or ongoing viremia and therefore affects evaluation, treatment, and transplantation decisions.

Chronic Disease and Kidney Consequences

The natural history of chronic hepatitis C virus infection in Europe is prolonged and variable. Fibrosis may advance over several decades, from minimal hepatic change to chronic hepatitis, extensive fibrosis, cirrhosis, and hepatocellular carcinoma. Between 10% and 40% of patients may develop cirrhosis depending on cofactors such as alcohol consumption, tobacco or cannabis use, metabolic syndrome, diabetes mellitus, older age at acquisition, HIV coinfection, or infection with other hepatotropic viruses. In cirrhotic patients, hepatocellular carcinoma has an estimated incidence of 3% per year, while death from complications of cirrhosis occurs at about 4% per year.

Europe is also a major context for the association between hepatitis C virus infection and chronic kidney disease. In patients with hepatitis C virus infection, including kidney or liver transplant recipients, glomerular lesions may occur with or without advanced liver disease; patients with hepatitis C virus-associated glomerulonephritis are described as positive for hepatitis C virus RNA in serum. A United States comparison cited in the European medical literature found that infected patients had a higher risk of developing chronic kidney disease stages 3–5, while another study reported chronic kidney disease in 9.6% of anti-hepatitis C virus-positive patients compared with 5.1% of negative controls. Higher baseline viral load independently predicted chronic kidney disease, and infected patients reached chronic kidney disease and end-stage renal disease sooner.

European dialysis populations illustrate the broader consequences of infection. Across Europe, reported hepatitis C virus prevalence among people with kidney failure has ranged from 3% in the United Kingdom to 44% in Poland. A Spanish kidney-disease registry recorded 788 seropositive patients among 19,114 dialysis patients in 2007, a prevalence of 4%. These figures coexist with the wider global observation that prevalence among people with kidney failure can be far higher in some settings, demonstrating that regional estimates depend heavily on local health systems, historical transfusion exposure, infection-control practice, and diagnostic coverage.

Hemodialysis and Infection Control

The history of hepatitis C virus in European hemodialysis units changed after the virus was identified as the principal cause of non-A, non-B hepatitis in 1989. During the early 1990s, hemodialysis patients were recognized as a high-risk group. Their risk initially reflected frequent transfusion, but several findings supported continuing nosocomial transmission: prevalence correlated with time on dialysis independently of transfusion burden, was higher in hemodialysis than in peritoneal dialysis or home hemodialysis, and remained substantial among patients who had never received transfusions.

As blood-donor screening improved and erythropoiesis-stimulating agents became widely available, transfusion-related transmission declined sharply. The cited risk of post-transfusion hepatitis C virus infection fell from approximately 0.5% per blood unit in the 1980s to about 0.0001%, or one case per million blood units, in the United States, with comparable improvements reported in other Western countries. Attention consequently shifted toward transmission within dialysis units, where contaminated hands, gloves, equipment, surfaces, or procedures could connect infected and susceptible patients even when they did not share the same machine.

Molecular virology made this concern demonstrable. From the mid-1990s onward, phylogenetic analyses identified clusters of closely related hepatitis C virus isolates among patients treated in the same hemodialysis unit. Variable portions of the viral genome allowed investigators to fingerprint isolates and compare genetic relatedness with epidemiological information. In a systematic review of 20 studies involving newly diagnosed infected patients and previously infected source patients, every study implicated failures in infection-control procedures as the probable cause, although none conclusively established a specific transmission route.

The same review limited the role assigned to the dialysis machine itself. In 18 of 20 studies, some or all newly infected patients had not shared a machine with the source patient; they either underwent dialysis at the same time or were assigned machines different from those used by infected patients. The internal machine circuit therefore appeared to play, at most, a small role. On that basis, the KDIGO workgroup did not recommend dedicated machines for infected patients and did not recommend isolating infected patients in a separate ward as an alternative to strict infection-control procedures. Large prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study and an Italian study, found no protective effect from isolation after adjustment for confounding factors.

The recommended European approach emphasizes ordinary but rigorously applied hygiene. Staff should wash their hands with soap or antiseptic wash and water before and after contact with a patient or equipment, use alcohol gel when hands are not visibly contaminated, wear disposable gloves when caring for a patient or touching potentially contaminated surfaces, and remove gloves before leaving the dialysis station. Single-use items should be discarded after treatment; reusable equipment should be disinfected or dedicated to one patient; and dialysis-station surfaces should be cleaned after each session, with stronger disinfection for visibly contaminated areas. Regular observational audits and performance reviews are intended to turn infection control from a written policy into a monitored routine.

Survival, Quality of Life, and Treatment

The consequences of hepatitis C virus infection in European dialysis practice are not confined to the liver. A meta-analysis of seven observational studies involving 11,589 dialysis patients found an adjusted relative risk of 1.34 for all-cause mortality among anti-hepatitis C virus-positive patients. Liver-related mortality was especially prominent: hepatocellular carcinoma and cirrhosis were more frequent among seropositive patients, and the unadjusted risk of liver-related death was estimated at 5.89. The evidence also suggested an excess cardiovascular burden, although the cited meta-analysis found no statistically significant increase in cardiovascular-related mortality, with an unadjusted relative risk of 0.95.

Quality of life provides another route through which infection may affect survival. In a study of 165 regular dialysis patients, 83 of whom were anti-hepatitis C virus positive, infection was independently associated with a lower mental component score on the 36-item Short Form Health Survey, while no association was found with the physical component score. Depression, fatigue, cognitive impairment, concern about long-term health, and the psychological effect of being labeled as infected were proposed as possible contributors. Because dialysis itself is associated with depression, hepatitis C virus may add a mental-health burden to an already demanding treatment environment.

The progression of liver disease may nevertheless be slower in dialysis patients than in non-uremic patients. The hemodialysis procedure itself may reduce viral load, possibly through intradialytic production of interferon-alpha, hepatocyte growth factor, or other cytokines with antiviral activity, although the mechanism remains speculative. This apparent biological restraint does not eliminate the need for treatment: patients may still face cirrhosis, hepatocellular carcinoma, reduced quality of life, and increased mortality.

For chronic infection, the treatment framework described in the evidence is built mainly around pegylated interferon and ribavirin, with a mean sustained virologic response of about 60% in the general chronic-infection discussion. Sustained virologic response corresponds to viral eradication and permits the inactivation of necroinflammation and remodeling of fibrosis. For genotype 1 infection, treatment in 2011 could involve triple therapy with telaprevir or boceprevir, pegylated interferon, and ribavirin; for genotypes 2–6, the combination of pegylated interferon and ribavirin was described as the principal approach. New direct-acting antivirals and other oral agents were being developed to improve safety and efficacy, a development especially relevant to patients whose kidney disease, dialysis dependence, or transplant status complicated treatment choices.

Transplant Evaluation and Organ Allocation

Europe’s transplant systems place hepatitis C virus status within a longer chain of screening, staging, monitoring, and organ allocation. Between 10% and 25% of kidney-transplant candidates may have advanced liver injury, including stage 3 or 4 fibrosis or cirrhosis, when assessed by biopsy during pretransplant evaluation. Candidates should therefore be screened for anti-hepatitis C virus antibodies and, where appropriate, active viremia by nucleic acid testing. For patients with active infection, liver biopsy remains the reference method for determining advanced liver disease when noninvasive markers are insufficient.

Established or decompensated cirrhosis changes the transplant pathway. Such patients should be referred to a liver-transplant team for consideration of combined liver-kidney transplantation rather than proceeding automatically toward kidney transplantation alone. Patients on the kidney-transplant waiting list require regular monitoring for progressive liver disease, a particularly important safeguard where waiting times may approach five to seven years. The evidence describes no consensus on treating active viremia before kidney transplantation, although sustained virologic response before transplantation was thought, on largely anecdotal evidence, potentially to reduce post-transplant diabetes and immune-complex-mediated glomerular disease in the allograft.

European transplantation policy also addresses kidneys from hepatitis C virus-positive donors. Their use in hepatitis C virus-positive recipients has historically varied widely between centers, but center-based and registry experiences described long-term outcomes as apparently safe, with favorable graft survival, patient survival, and hepatitis C virus-related liver disease. International recommendations consequently limited this practice to recipients with positive hepatitis C virus RNA while on the waiting list who consented in advance. Matching donor and recipient viral genotypes might reduce the risk of superinfection, although the approach is constrained by the time available for allocation.

This policy has acquired an organizational dimension as infection prevalence falls and more patients with end-stage renal disease receive antiviral treatment before being listed. Hepatitis C virus-positive kidneys may become surplus organs because fewer suitable positive recipients remain, even while the overall organ shortage is severe. The evidence therefore supports measures such as offering these kidneys for preemptive transplantation, considering recipients who are not candidates for interferon therapy, and using international cooperation when suitable recipients cannot be found locally. Important limitations remain: donor RNA status was not consistently available, donor and recipient genotypes were often unreported, and liver histology was not systematically assessed. The favorable clinical outcomes therefore do not fully settle questions about superinfection or long-term histological fibrosis.

Regional Significance

Europe’s significance in the evidence lies in the way a regional setting exposes the full life cycle of hepatitis C virus management. It contains widely differing prevalence levels, records the transition from transfusion-dominated risk to infection-control concerns in dialysis, and shows how molecular sequencing can convert suspected nosocomial spread into epidemiological evidence. It also connects population screening with individual decisions about antiviral treatment, liver biopsy, waiting-list surveillance, combined transplantation, and the acceptance of a hepatitis C virus-positive kidney.

The European picture is consequently one of declining transmission but persistent consequences. Better blood safety and hygiene have reduced new infections, yet chronic cases continue to emerge through long silent disease, and dialysis and transplant populations remain vulnerable to liver, renal, cardiovascular, psychological, and graft-related complications. The region’s medical response depends not on a single intervention but on a coordinated system in which diagnosis distinguishes active viremia from past exposure, infection control prevents avoidable spread, treatment seeks viral eradication, and transplant policy weighs organ scarcity against the risks of hepatitis C virus transmission and progression.